Skip to content

Taysha Gene Therapies

US · TSHA #3015 by market cap Listed 2020
3.72 -0.05 -1.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/5/7
  • BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14
    Market Newswire · 2026/11/14
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $14
    Market Newswire · 2026/6/23
  • CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/11/13
  • Rating change
    Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/8/12
  • Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/10/16
  • Rating change
    Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/6/30
  • Rating change
    A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15
    Market Newswire · 2026/7/1
  • Rating change
    BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/6/23
  • Rating change
    Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)
    TipRanks · 2026/6/30
  • Rating change
    Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19
    Market Newswire · 2026/8/12
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/6/1
  • Rating change
    Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating
    Market Newswire · 2026/9/17
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/5/22
  • Earnings Flash (TSHA) Taysha Gene Therapies Posts Q3 Net Loss $0.10 a Share, Vs. FactSet Est of $0.13 Loss
    MT Newswires · 2026/11/12
  • BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
    Market Newswire · 2026/8/14
  • Rating change
    Citizens JMP Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/6/23
  • Rating change
    Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2026/8/12
  • Rating change
    Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/6/30
  • Rating change
    Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2026/7/22
  • Rating change
    CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/8/12
  • Rating change
    CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17
    Market Newswire · 2026/4/6
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14
    Market Newswire · 2026/7/1
  • Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/8/12

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Taysha Gene Therapies discussion 0 comments

Add a comment